Bee venom as a promising therapeutic strategy in central nervous system diseases

• Published in: Neuropeptides (Edinburgh) Vol. 107; p. 102451
• Main Authors: Vahidinia, Zeinab, Barati, Shirin, Azami Tameh, Abolfazl, Bagheri-Mohammadi, Saeid, Garshasebi, Ali
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.10.2024
• Subjects: Animals; Apitherapy; Bee venom; Bee Venoms - pharmacology; Bee Venoms - therapeutic use; Central nervous system diseases; Central Nervous System Diseases - drug therapy; Central Nervous System Diseases - metabolism; Humans; Melittin; Phospholipase A2; Phospholipases A2 - metabolism; BVT; TNFα; Melittin; JNK; ALS; 6-OHDA; Aβ; NF-κB; PI3K; PNS; Th1; 3-AP; IFN- γ; MAPKs; Phospholipase A2; Central nervous system diseases; EAE; PLA2; IL-1β; Apitherapy; MMP; MIP; XIST; TLR4; Bcl-2; FDA; MCP-1; COX- 2; PON1; MAC-1; CNS; PARP; Iba1; LPS; TRPM2; CREB; BV; BuChE; Nrf2; SK; TGF-β; PGE2; Bee venom; BDNF; Tregs; STAT3; Akt; BAK; GFAP; MCD; TrkB; PLC-γ1; BAX; mtSOD1; MPTP
• ISSN: 0143-4179; 1532-2785; 1532-2785
• DOI: 10.1016/j.npep.2024.102451

Central nervous system (CNS) disorders are one of the leading health problems today, accounting for a large proportion of global morbidity and mortality. Most these disorders are characterized by high levels of oxidative stress and intense inflammatory responses in degenerated neuronal tissues. While extensive research has been conducted on CNS diseases, but few breakthroughs have been made in treatment methods. To date, there are no disease-modifying drugs available for CNS treatment, underscoring the urgent need for finding effective medications. Bee venom (BV), which is produced by honeybee workers' stingers, has been a subject of interest and study across various cultures. Over the past few decades, extensive research has focused on BV and its therapeutic potentials. BV consists a variety of substances, mainly proteins and peptides like melittin and phospholipase A2 (PLA2). Research has proven that BV is effective in various medical conditions, including pain, arthritis and inflammation and CNS disorders such as Multiple sclerosis, Alzheimer's disease and Parkinson's disease. This review provides a comprehensive overview of the existing knowledge concerning the therapeutic effects of BV and its primary compounds on various CNS diseases. Additionally, we aim to shed light on the potential cellular and molecular mechanisms underlying these effects.